Generics 4

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Sugammadex sodium manufacturers

4 products found

Filters

4 products found

sugammadex sodium

Solution for injection 200 mg/2 ml, 500 mg/5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Bridion®MSD
Manufacturer #8822
A pharmaceutical manufacturer based in Europe that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, and Asia for 50+ years. The main therapeutic areas include CNS, ophthalmology, and dermatology. Main dosage forms include sterile and solid oral dosage forms. The company's production lines are cGMP-compliant. The company possesses branches in Europe, North America, and Asia.

Manufacturer usually replies in 5 days

sugammadex sodium

Vials, injection 100 mg/ml - 2 ml, 5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, EU GMP
Unavailable markets
Australia , Malaysia , Peru
Registered in
Austria , Belgium , Czech Republic , France , Germany , Ireland , Italy , Poland , Portugal , Slovakia , Spain , United Kingdom
Available for
Licensing with supply, Distribution only
MAs for sale
Austria , Belgium , Czech Republic , France , Germany , Ireland , Italy , Poland , Portugal , Slovakia , Spain , United Kingdom
Comments
MAs available: DE, UK, AT, ES, FR, IE, IT, PT, BE, PL, CZ, SK
Manufacturer #16394

Manufacturer usually replies in 13 days

sugammadex sodium

Solution for injection 200 mg , 500 mg - 2 ml , 5 ml

Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Manufacturer #12677

Manufacturer usually replies in 4 days

sugammadex sodium

Solution for injection 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #1356

Sugammadex sodium:

Sugammadex sodium, also commonly for sale under the brand name of Bridion, is a medication used in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. Additionally, it is also used in general anaesthesia, where its common side effects include cough, airway problems due to the anaesthesia wearing off, reduced blood pressure, along with other complications such as changes in heart rate.
It belongs to a group of pharmaceutical products termed first selective relaxant binding agents and it was originally discovered by the pharmaceutical manufacturing company Organon at the Newhouse Research Site in Scotland. In recent years, Organon was acquired by the drugs manufacturing company Schering-Plough in 2007, which subsequently merged with Merck in 2009, who now owns the rights to Sugammadex. Currently, Sugammadex sodium manufacturers and Sugammadex sodium suppliers have gained approval for its commercial medical use in the European Union in 2008 and by the FDA in the United States in 2015. It can now be found for sale and wholesale, in a cost efficient manner, by distributors at varying price points across the global marketplace.

Method of action of sugammadex sodium:

Sugammadex sodium is produced by manufacturers to bind to the neuromuscular blocking agents rocuronium or vecuronium, forming a complex that inhibits their function. It functions in a way that does not affect the release or breakdown of acetylcholine. This is enabled through reducing free rocuronium in the plasma, which creates a concentration gradient with the neuromuscular junction. As a result, rocuronium or vecuronium are drawn to the plasma, where it is subsequently encapsulated. This reduces the availability of the neuromuscular blocking agent to bind to nicotinic cholinergic receptors in the neuromuscular junction, culminating in the reversal of neuromuscular blockade.

Form and dosage of Sugammadex sodium:

As with all drugs, the final form and packaging of Sugammadex sodium are dependent on the manufacturers, suppliers, and intended distributor or order. However, Sugammadex sodium typically comes in forms including vials, solution for injection, and solution for infusion, where it is administered intravenously. It is a specialised medication, as such it can only be administered by a medical professional, with typical dosages for adults in the routine reversal of neuromuscular blockade induced by rocuronium or vecuronium, being an initial 2–4 mg/kg followed by 4 mg/kg if required. For the Immediate reversal of neuromuscular blockade induced by rocuronium, 16 mg/kg for adults is recommended by the literature.

Sugammadex sodium on Pipelinepharma:

Currently, at the time of writing, there are 3 trusted sugammadex sodium manufacturers and sugammadex sodium suppliers available on our B2B global list of online wholesale distributors. These sellers are located in various countries including India, and the European Union. Both the sellers and their pharmaceutical products list have been verified by the Pipelinepharma team according to strict quality control. This facilitates a rapid and painless sourcing experience for both parties by ensuring no time is wasted on dead ends.

Price of Sugammadex sodium and how to buy:

Like all drugs, the cost of Sugammadex sodium can vary greatly depending on numerous factors such as market condition, location, and organisation. However, a cursory search online reveals 25 mg of wholesale bulk Sugammadex sodium is priced at approximately USD 102.36. Although the specific cost on the Pipelinepharma online marketplace remains confidential between both B2B parties, pending agreement and negotiation, manufacturers or suppliers may choose to list their desired price for the product. If so, this will be indicated with an ‘Accept’ and ‘Negotiate’ button and in the absence of a price, a ‘Get offer’ button will instead be displayed.